Access Pharmaceuticals Reports Significant Oral Bioavailability of Cobalamin(TM) Oral Insulin in Additional Studies
Cobalamin Seen As Broadly Applicable For Oral Delivery Of Many Large Molecule Drugs Now Administered By Injection
DALLAS, March 11 /PRNewswire-FirstCall/ -- ACCESS
PHARMACEUTICALS, INC. (OTC:ACCP) (BULLETIN BOARD: ACCP) announced that
it has received reports of significant bioavailability of orally
delivered insulin in two independently-conducted animal studies.
The studies, which confirm earlier findings, were performed as part
of on-going work with commercial collaborators that are evaluating
Access' Cobalamin(TM) Oral Drug Delivery Technology.
Access previously reported that its novel Cobalamin-coated
insulin containing nanoparticle formulations delivered orally
provided a pharmacological response (lowering of blood glucose
levels in animal models) equivalent to greater than 80% of that
achieved by insulin delivered subcutaneously. The Company believes
the substantial oral bioavailability found underscores the
formulation's potential for clinical development and ultimate
commercialization. Additionally, Access believes that its Cobalamin
Oral Drug Delivery Technology has broad application to proteins,
small molecule drugs, hormones, and potentially sRNAi
In addition to insulin, adaptation of this technology has
provided a Cobalamin human growth hormone (HGH) formulation that
has demonstrated good efficacy, represented by more than 25%
improvement in weight gain, when given orally in an established
animal model. Access continues moving its insulin and HGH products
towards clinical development, while submitting additional patents
surrounding both formulations.
"We remain excited about the potential of our Cobalamin oral
drug delivery technology, and the positive data being generated,"
stated Jeff Davis, CEO of Access Pharmaceuticals, Inc.
Access' worldwide-exclusive patented Cobalamin technology
utilizes the body's natural vitamin B12 oral uptake to facilitate
oral absorption of pharmaceuticals by a "Trojan horse" mechanism.
This technology platform provides Access with the ability to
develop a number of different formulations with improved benefits
for various disease applications.
"We have several ongoing discussions with other companies
regarding the application of our oral drug delivery options for
their promising new drugs. Additionally, we continue exploring ways
to move this to a proof-of-concept human trial as quickly as
possible," commented Phillip Wise, Access' Vice President of
Business Development and Strategy.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical
company that develops and commercializes proprietary products for
the treatment and supportive care of cancer patients. Access'
products include ProLindac(TM), currently in Phase II clinical
testing of patients with ovarian cancer, and MuGard(TM) for the
management of patients with mucositis. The company also has other
advanced drug delivery technologies including
Cobalamin(TM)-mediated targeted delivery and oral drug delivery,
its proprietary nanopolymer delivery technology based on the
natural vitamin B12 uptake mechanism and Thiarabine, a new
generation nucleoside analog which has demonstrated both
pre-clinical and clinical activity in certain cancers. For
additional information on Access Pharmaceuticals, please visit our
website at www.accesspharma.com.
This press release contains certain statements that are
forward-looking within the meaning of Section 27a of the Securities
Act of 1933, as amended, and that involve risks and uncertainties.
These statements include those relating to: our cash burn rate,
clinical trial plans and timelines and clinical results for
ProLindac, MuGard, Thiarabine and Cobalamin and other product
candidates, our ability to achieve clinical and commercial success
and our ability to successfully develop marketed products. These
statements are subject to numerous risks, including but not limited
Access' need to obtain additional financing in order to continue
the clinical trial and operations and to the risks detailed in
Access' Annual Reports on Form 10-K and other reports filed by
Access with the Securities and Exchange Commission.
Contact: Company ---------------- Stephen B. Thompson Vice President, Chief Financial Officer Access Pharmaceuticals, Inc. (214) 905-5100 Christine Berni Director of Investor Relations Access Pharmaceuticals, Inc. (212) 786-6208 Contact: Investor Relations --------------------------- Donald C. Weinberger/Diana Bittner (media) Wolfe Axelrod Weinberger Assoc. LLC (212) 370-4500
Source: Access Pharmaceuticals, Inc.
CONTACT: Stephen B. Thompson, Vice President, Chief Financial
Access Pharmaceuticals, Inc., +1-214-905-5100; Christine Berni, Director of
Investor Relations, Access Pharmaceuticals, Inc., +1-212-786-6208; Donald C.
Weinberger or Diana Bittner, Wolfe Axelrod Weinberger Assoc. LLC,
Web Site: http://www.accesspharma.com/
Posted: March 2010